Growth Hormone Replacement Therapy in Veterans with Gulf War Illness and GH Deficiency

Abstract

This study is a feasibility trial of recombinant human growth hormone (rhGH) replacement therapy (using somatropin) in Veterans from Operations Desert Storm/Desert Shield with a history of Gulf War Illness (GWI) with adult growth hormone deficiency (AGHD). This study will assess the efficacy and safety of rhGH in this population, as well as treatment compliance. The primary hypothesis is that participants receiving rhGH for 6-months will show improvements in body composition (i.e., truncal fat mass reduction of 5.3% or greater) compared to placebo.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
Oct 01, 2023
Accession Number
AD1221161

Entities

People

  • José M. Garcia
  • Ricardo Jorge

Organizations

  • Baylor College of Medicine

Tags

Readers

  • Gulf War Illness and Chronic Multisymptom Illness in Veterans.
  • Life Cycle Cost Analysis